Tirzepatide: Dual-Receptor Mechanism, Dosing, and Results
Why tirzepatide's two receptors can produce more weight loss, the full titration chart, side effects, and compounded versus brand.
Mechanism of Action
How this molecule works at the cellular level.
Tirzepatide injected
Once-weekly subcutaneous dual-pathway dose
Two incretin pathways
GIP plus primary gut incretin receptors activated
Appetite and metabolism
Reduced appetite, slowed gastric emptying, improved insulin sensitivity
Clinical outcome
Up to about 21% mean weight loss, superior to semaglutide head-to-head
Tirzepatide injected
Once-weekly subcutaneous dual-pathway dose
Two incretin pathways
GIP plus primary gut incretin receptors activated
Appetite and metabolism
Reduced appetite, slowed gastric emptying, improved insulin sensitivity
Clinical outcome
Up to about 21% mean weight loss, superior to semaglutide head-to-head
What tirzepatide is
Tirzepatide is a dual agonist: it activates both the GLP-1 receptor and the GIP receptor. GLP-1 reduces appetite and slows gastric emptying; GIP is a second incretin hormone that appears to improve insulin sensitivity and how the body handles fat. Hitting two pathways instead of one is the structural reason tirzepatide behaves differently from single-pathway drugs.
How it compares on weight loss
In its pivotal obesity trial (SURMOUNT-1), tirzepatide produced up to about 21% mean body-weight reduction at the 15 mg dose over 72 weeks. In a head-to-head trial against semaglutide (SURMOUNT-5), tirzepatide produced more weight loss (roughly 20% versus 14% mean), with a larger share of participants reaching the 15% and 20% thresholds. On current evidence it is the more powerful weight-loss approach on average, though "on average" matters: the right medication for any individual depends on labs, budget, and tolerance. See our full tirzepatide vs semaglutide comparison.
Tirzepatide dosing chart
Tirzepatide is a once-weekly subcutaneous injection that steps up roughly every 4 weeks. The standard titration is:
- Weeks 1-4: 2.5 mg once weekly (starting dose, not therapeutic)
- Weeks 5-8: 5 mg once weekly
- Weeks 9-12: 7.5 mg once weekly
- Weeks 13-16: 10 mg once weekly
- Weeks 17-20: 12.5 mg once weekly
- Week 21 onward: 15 mg once weekly (maximum maintenance)
Maintenance is commonly 5, 10, or 15 mg depending on response and tolerance. Not everyone needs to reach 15 mg. The goal is the lowest dose that delivers steady progress without intolerable side effects, and your provider will hold or slow the schedule if needed.
Side effects
The side-effect profile is broadly similar to semaglutide because both slow the gut: nausea, constipation, diarrhea, and reflux, worst in the weeks after a dose increase and usually improving with time. Gallbladder issues and pancreatitis are uncommon but real (report severe, persistent abdominal pain immediately). Tirzepatide carries the same boxed warning regarding thyroid C-cell tumors and is not appropriate with a personal or family history of medullary thyroid carcinoma or MEN2.
What KAYU prescribes
KAYU prescribes brand-name, FDA-approved tirzepatide for weight management (Zepbound®) dispensed by licensed pharmacies at their published cash-pay price. We do not prescribe compounded tirzepatide. Your provider tells you exactly which product is being prescribed and what it costs before you start.
The KAYU approach
Tirzepatide treatment plans at KAYU start with the same full metabolic panel as any incretin-based weight-loss treatment plan, because the medication is the easy decision and the underlying metabolic picture is the important one. Your provider builds the treatment plan with a muscle-preservation plan and a defined maintenance and off-ramp strategy, not a prescription and a wish of luck.
References
- [1]Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine. DOI: 10.1056/NEJMoa2206038
- [2]Aronne LJ, Horn DB, le Roux CW, et al. (2025). Tirzepatide versus semaglutide for the treatment of obesity (SURMOUNT-5). New England Journal of Medicine. DOI: 10.1056/NEJMoa2416394
Ready to feel rooted?
Two minutes to the assessment. One week to your first consult. A treatment plan built on your bloodwork from a provider who knows your name.